Napa, CA (May 21, 2007) -- Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist™ (formoterol fumarate) Inhalation Solution, delivered by ...

August 16, 2010 — Nebulized hypertonic 3% saline solution without adjunctive bronchodilators has a low rate of adverse events in infants younger than 2 years with bronchiolitis, according to the ...

- LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) available for the treatment of COPD in the U.S. - MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc.

Perforomist is a solution formulation of the long-acting beta 2-agonist formoterol fumarate, which is administered by inhalation via nebulization. It acts as a bronchodilator by stimulating beta 2 ...

- LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S. - MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc.

The drug will be available in one strength with a fixed dose to be taken once daily. (File) Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United ...

The major pharma will present the exploratory analysis of survival in patients and various clinical outcomes of these products. (File) Alembic Pharmaceuticals Ltd on Wednesday said it has received ...

Drug major Cipla on Wednesday said it has received final approval from the US health regulator for Arformoterol Tartrate Inhalation Solution, used to treat conditions like chronic bronchitis and ...

Global pharma major Lupin Limited on Tuesday announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), ...